Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information
Phone33 1 58 33 50 00


Boulogne-Billancourt, FRA
65 Quai Georges Gorse
Boulogne-Billancourt, 92100, FRA


Show All People


Syntaxin, 7/2013 $206M
Octagen, 6/2008 $36.5M
Tercica, 6/2008 $480M




Ipsen S.A. engages in the research, development, manufacture, and sale of pharmaceutical products worldwide. The company markets approximately 20 drugs. It offers pharmaceutical products targeting oncology, endocrinology, and neuromuscular disorders, as well as gastroenterology, cardiovascular, and cognitive disorders. Products The company’s products include: Decapeptyl is a peptide formulation for injection used to treat advanced prostate cancer. Somatuline and Somatuline Autogel is a sustained-release formulations for injection of a somatostatin analogue peptide for treating acromegaly. NutropinAq is a liquid formulation for daily use of recombinant human growth hormone used in the treatment of growth failures. Increlex is a recombinant human Insulin-like Growth-Factor-1 for normal growth of bones. Dysport acts to block acetylcholine release for the treatment of motor disorders and various forms of muscular spasticity, including cervical dystonia. Smecta is an oral formulation of pharmaceutical clay used for the treatment of chronic and acute diarrhea in adults and children and in the symptomatic treatment of pain associated with esophageal, gastric, duodenal, or colonic disorders. Forlax is used for the treatment of constipation for adults and children. Tanakan is an oral formulation of EGb 761, extracted from the leaves of the Gingko biloba tree, is used in the treatment of age-related cognitive disorders. As of December 31, 2007, Tanakan is approved for use in approximately 60 countries, including Europe and Asia. Adrovance is used for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D deficiency. Adenuric is used for the treatment of chronic hyperuricaemia. Nisis and Nisisco is an oral formulations containing valsartan for treating arterial hypertension. Significant Events On June 15, 2009, Ipsen S.A. and Pharnext SAS announced that they have entered into an exclusive research, development and marketing agreement regarding innovative drug candidates intended for the treatment of Charcot Marie-Tooth disease, issued from the Pleotherapy technology. History Ipsen S.A. was founded in 1929.

Recent Milestones




  1. Ipsen to Acquire Syntaxin for $206 ( [edit]
  2. Ipsen SA acquires Octagen Corp-OBI-1 Assets from Octagen Corp ( [edit]
  3. Ipsen to Acquire Tercica ( [edit]
  4. Rhythm Adds $8M to Cap Series B at $33M ( [edit]
  5. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics ( [edit]
  6. Biomeasure to get $45M investment from Ipsen ( [edit]
  7. VCs inject $29M into Syntaxin, $11.5M into Ceregene ( [edit]
  8. Bélingard to leave Ipsen, de Garidel named CEO ( [edit]
Edit This Page
Last Edited 2/21/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy